These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 24687512)

  • 21. Ten-Day Quadruple Therapy Comprising Proton Pump Inhibitor, Bismuth, Tetracycline, and Levofloxacin is More Effective than Standard Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori Infection: A Randomized Controlled Trial.
    Hsu PI; Tsai FW; Kao SS; Hsu WH; Cheng JS; Peng NJ; Tsai KW; Hu HM; Wang YK; Chuah SK; Chen A; Wu DC
    Am J Gastroenterol; 2017 Sep; 112(9):1374-1381. PubMed ID: 28719592
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibiotic resistance problems with Helicobacter pylori.
    Alarcón T; Domingo D; López-Brea M
    Int J Antimicrob Agents; 1999 Jun; 12(1):19-26. PubMed ID: 10389643
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Susceptibility-guided therapy for Helicobacter pylori-infected penicillin-allergic patients: A prospective clinical trial of first-line and rescue therapies.
    Luo L; Huang Y; Liang X; Ji Y; Yu L; Lu H
    Helicobacter; 2020 Aug; 25(4):e12699. PubMed ID: 32428369
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro characterization of the anti-bacterial activity of SQ109 against Helicobacter pylori.
    Makobongo MO; Einck L; Peek RM; Merrell DS
    PLoS One; 2013; 8(7):e68917. PubMed ID: 23935905
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of antimicrobial activity of zinc chloride and bismuth subsalicylate against clinical isolates of Helicobacter pylori.
    Yakoob J; Abbas Z; Usman MW; Awan S; Naz S; Jafri F; Hamid S; Jafri W
    Microb Drug Resist; 2014 Aug; 20(4):305-9. PubMed ID: 23844851
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication.
    Sun Q; Liang X; Zheng Q; Liu W; Xiao S; Gu W; Lu H
    Helicobacter; 2010 Jun; 15(3):233-8. PubMed ID: 20557366
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gastroprotective effects of Hwanglyeonhaedok-tang against Helicobacter pylori-induced gastric cell injury.
    Park HS; Wijerathne CUB; Jeong HY; Seo CS; Ha H; Kwun HJ
    J Ethnopharmacol; 2018 Apr; 216():239-250. PubMed ID: 29410309
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimum duration of regimens for Helicobacter pylori eradication.
    Yuan Y; Ford AC; Khan KJ; Gisbert JP; Forman D; Leontiadis GI; Tse F; Calvet X; Fallone C; Fischbach L; Oderda G; Bazzoli F; Moayyedi P
    Cochrane Database Syst Rev; 2013 Dec; (12):CD008337. PubMed ID: 24338763
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Monotherapy with mastic does not eradicate Helicobacter pylori infection from mice.
    Loughlin MF; Ala'Aldeen DA; Jenks PJ
    J Antimicrob Chemother; 2003 Feb; 51(2):367-71. PubMed ID: 12562704
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the efficacy of 1-day high-dose quadruple therapy versus 7-day triple therapy for treatment of Helicobacter pylori infection.
    Zheng Q; Pan Y; Zhang L; Xiao SD
    Chin J Dig Dis; 2005; 6(4):202-5. PubMed ID: 16246231
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of real-time PCR-based detection of Helicobacter pylori infection and genotypic resistance-guided quadruple therapy as the first-line treatment for functional dyspepsia with Helicobacter pylori infection.
    Liu Q; Qi D; Kang J; Jin Y; Liu W; Gao W; Hou P; Lu J
    Eur J Gastroenterol Hepatol; 2015 Mar; 27(3):221-5. PubMed ID: 25629566
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Favorable outcomes of culture-based Helicobacter pylori eradication therapy in a region with high antimicrobial resistance.
    Lee JW; Kim N; Nam RH; Lee SM; Kwon YH; Sohn SD; Kim JM; Lee DH; Jung HC
    Helicobacter; 2019 Apr; 24(2):e12561. PubMed ID: 30632237
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Helicobacter pylori and antimicrobial resistance: molecular mechanisms and clinical implications.
    Gerrits MM; van Vliet AH; Kuipers EJ; Kusters JG
    Lancet Infect Dis; 2006 Nov; 6(11):699-709. PubMed ID: 17067919
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication.
    Tanabe H; Yoshino K; Ando K; Nomura Y; Ohta K; Satoh K; Ichiishi E; Ishizuka A; Otake T; Kohgo Y; Fujiya M; Okumura T
    Ann Clin Microbiol Antimicrob; 2018 Jun; 17(1):29. PubMed ID: 29950163
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 'Rescue' therapies for the management of Helicobacter pylori infection.
    Di Mario F; Cavallaro LG; Scarpignato C
    Dig Dis; 2006; 24(1-2):113-30. PubMed ID: 16699270
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Understanding treatment guidelines with bismuth and non-bismuth quadruple Helicobacter pylori eradication therapies.
    Graham DY; Dore MP; Lu H
    Expert Rev Anti Infect Ther; 2018 Sep; 16(9):679-687. PubMed ID: 30102559
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro and in vivo anti-Helicobacter/Campylobacter activity of the aqueous extract of Enantia chlorantha.
    Tan PV; Boda M; Etoa FX
    Pharm Biol; 2010 Mar; 48(3):349-56. PubMed ID: 20645825
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quadruple therapy is effective for eradicating Helicobacter pylori after failure of triple proton-pump inhibitor-based therapy: a detailed, prospective analysis of 21 consecutive cases.
    Gomollón F; Ducóns JA; Ferrero M; García Cabezudo J; Guirao R; Simón MA; Montoro M
    Helicobacter; 1999 Dec; 4(4):222-5. PubMed ID: 10597390
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    Xu YF; Lian DW; Chen YQ; Cai YF; Zheng YF; Fan PL; Ren WK; Fu LJ; Li YC; Xie JH; Cao HY; Tan B; Su ZR; Huang P
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28320722
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bovine lactoferrin enhances the efficacy of levofloxacin-based triple therapy as first-line treatment of Helicobacter pylori infection: an in vitro and in vivo study.
    Ciccaglione AF; Di Giulio M; Di Lodovico S; Di Campli E; Cellini L; Marzio L
    J Antimicrob Chemother; 2019 Apr; 74(4):1069-1077. PubMed ID: 30668729
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.